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Background: Patient treatment satisfaction is likely to be a highly relevant outcome measure in pulmonary arterial
hypertension (PAH), a condition for which the benefits of treatment must be weighed against frequent, undesirable
side effects, inconvenience, and complications associated with therapy. In this study, we sought to evaluate the
psychometric properties of a patient-reported treatment satisfaction measure and its relationship to quality of life
(QoL) among patients transitioning from inhaled iloprost (iILO) to inhaled treprostinil (iTRE).
Methods: We studied treatment satisfaction among 66 subjects with PAH in a single-arm, open-label, multi-center
trial of iTRE following transition from iILO. Treatment satisfaction was assessed using the Treatment Satisfaction
Questionnaire for Medication (TSQM, version 1.4) administered to subjects immediately before and 12 weeks after
transition of inhaled therapy. The TSQM is comprised of 4 domains: effectiveness, side effects, convenience, and global
satisfaction. Scores range from 0 to 100 with higher scores indicating greater satisfaction. Six-minute walk distance
(6MWD), functional class, adverse events, drug administration time, and PAH-specific QoL (CAMPHOR) were
concurrently assessed.
Results: Domains of the TSQM demonstrated evidence of strong internal consistency at baseline and at 12 weeks
(Cronbach α = 0.88-0.93). Transition from iILO to iTRE was associated with an improvement in 3 of 4 TSQM domains:
effectiveness (+20 ± 21, p < 0.0001), side effects (0 ± 22, p = 0.97), convenience (+39 ± 26, p < 0.0001), and global
satisfaction (+20 ± 24, p = 0.0005). Change in effectiveness scores correlated with change in 6MWD (r = 0.43,
p = 0.0004) and side effects scores at 12 weeks correlated inversely with number of severity-weighted treatment-
emergent adverse events (r = −0.44, p = 0.0002). In multiple regression models adjusted for baseline characteristics,
changes in effectiveness and convenience satisfaction scores were significantly associated with improvement in PAH-
specific QoL (p = 0.002 and p = 0.01).
Conclusions: The TSQM demonstrated acceptable performance characteristics in patients with PAH. Changes in
treatment satisfaction resulting from transitioning from iILO to iTRE were associated with improvements in PAH-
specific QoL.
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Pulmonary arterial hypertension (PAH) is a life-threatening
disorder of the pulmonary vasculature historically associ-
ated with poor survival [1]. Advances in the diagnosis and
treatment of PAH over the past two decades appear to
have modestly improved overall survival [2-4]. Despite
improvements in life expectancy, quality of life (QoL) for
those living with the condition remains significantly im-
paired [5-7]. While several medications have been shown
to improve 6-minute walk distance (6MWD), the benefits
of treatment may be offset by intolerable side effects, need
for frequent monitoring, complicated delivery systems, and
the time required to prepare and administer therapy. In-
deed, qualitative studies designed to characterize PAH
from the patient’s perspective confirm that accommodating
treatment represents a substantial burden to patients and
has a negative impact on QoL [8-10].
In recent years, inhaled prostacyclin analogues have
emerged as an attractive treatment option [11]. Two in-
haled prostacyclin analogues are currently approved in
the United States for the treatment of PAH: iloprost and
treprostinil [12,13]. Both have been demonstrated in
clinical trials to increase exercise capacity in patients
with World Health Organization (WHO) Group 1 PAH
[14-16]. Due to a relatively short half life (20–30 -
minutes), iloprost has a recommended dosing regimen
of 6 to 9 inhalation sessions per day, each lasting 4 to
10 minutes. In contrast, treprostinil, which has a sub-
stantially longer half-life (4.5 hours), can be administered
4 times per day, each session lasting 2–3 minutes, with a
target maintenance dose of 9 breaths per session.
In a 12 week, multicenter, prospective, open-label trial
of stable PAH patients transitioned from inhaled iloprost
to inhaled treprostinil, total time spent on daily treat-
ment activities was reduced by an average of 1.4 hours
per day [17,18]. Significant improvement in 6MWD and
QoL scores were also observed. In that trial, data on
overall treatment satisfaction was concurrently assessed
using a recently validated patient-reported outcome
(PRO) measure, the Treatment Satisfaction Question-
naire for Medication (TSQM) [19]. The concept of treat-
ment satisfaction—although still relatively novel—has
gained increasing recognition over recent years [20-22].
Of the few instruments available to assess satisfaction
with treatment, the TSQM is one of the most widely
used. It has been applied across various conditions and
different modalities of treatment [19,23-25]. For ex-
ample, the validation cohort used to develop the TSQM
included common conditions such as migraine, arthritis,
hypertension, asthma, and diabetes, among others [19].
In that study, different routes of treatment administra-
tion were also evaluated, including oral, injection, top-
ical, and inhalation. Despite the obvious importance of
treatment satisfaction in conditions requiring intensivetherapy, it has not yet been studied in PAH. Because the
construct integrates the positive, as well as negative as-
pects of therapy, treatment satisfaction may be a particu-
larly relevant outcome for patients with PAH.
Using data collected within the context of a clinical trial,
we sought to evaluate the psychometric characteristics of
the TSQM assessed among patients with PAH transitioning
from inhaled iloprost to inhaled treprostinil. In addition, we
sought to determine whether changes in treatment satisfac-
tion were associated with observed changes in QoL.
Methods
Subjects
For this analysis, we utilized clinical and patient-reported
outcome data obtained from a multicenter, prospective,
open-label trial in patients with stable PAH rapidly
transitioned from inhaled iloprost to inhaled treprostinil
[17,18]. In brief, eligible patients were between the age of
18 and 75 years with a diagnosis of idiopathic/hereditary
PAH, PAH associated with collagen vascular disease or
human immunodeficiency virus, or PAH associated with
congenital systemic-to-pulmonary shunt. Patients were re-
quired to have a baseline 6MWD of ≥250 meters(m) and
be receiving a stable dose of iloprost for ≥30 days prior to
baseline. Patients were considered ineligible if they had
changed or discontinued any FDA-approved PAH medica-
tion within 30 days. Following completion of all baseline
study assessments, patients discontinued iloprost therapy
during the baseline visit and initiated inhaled treprostinil
at 3 breaths (6 μg/breath) four times daily (qid) at their
next scheduled dose of iloprost therapy. The suggested
treprostinil dose titration was an increase of one add-
itional breath per dosing session every three days with a
goal of 9 breaths qid within the first 3 weeks of treatment.
If clinically indicated, investigators were allowed to in-
crease to a maximum dose of 12 breaths qid. Following
institutional review board approval, all patients provided
informed consent before any study-related assessments.
Study assessments
Analysis was restricted to key outcomes of interest
collected at baseline and week 12: 6MWD, QoL, treatment
satisfaction, and medication administration time. In add-
ition, we included a Patient Impression of Change scale
administered at week 12 and data on study-emergent
adverse events (AEs).
Treatment satisfaction was assessed using the TSQM
(version 1.4) [19]. This questionnaire is comprised of 14
items which represent 4 domains: effectiveness, side effects,
convenience, and global satisfaction. TSQM scores range
from 0 to 100, higher scores indicating greater satisfaction.
Quality of life was assessed using the Cambridge Pulmo-
nary Hypertension Outcome Review (CAMPHOR) [26].
The CAMPHOR includes 3 separate subscales designed
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subscale is comprised of 25 items defined using a “needs-
based” conceptual model, which postulates that life gains
its quality from the ability and capacity of the individual
to satisfy his or her needs [27]. The CAMPHOR QoL
subscale ranges from 0 to 25 with lower scores repre-
senting better QoL. Medication administration time was
assessed using a drug administration activities survey for
which patients were asked to provide information related
to the frequency of daily administration activities and time
required by each activity (e.g., gathering and setting up
supplies, preparing drug delivery system, delivering inha-
lation treatment, and cleaning drug delivery system) for
inhaled iloprost (baseline) and inhaled treprostinil (week
12). AEs were summarized using a severity-weighted AE
score calculated as the sum of the 15 most common
study-emergent AEs, where each event was scored as 0 if
the event never occurred, 1 if the event was at most mild,
2 if the event was at most moderate, and 3 if the event
was severe. Potential scores range from 0 (least burden) to
45 (most burden). To independently assess the magnitude
of change in treatment satisfaction over time, we used a
global Patient Impression of Change measure comprised
of a single item with a 5-point Likert scale (“much more
satisfied”, “more satisfied”, “about the same”, “less satis-
fied”, “much less satisfied”).
Analysis
Sample size for the original prospective, open-label trial
was based on anticipated enrollment over the planned
timeline and not based on statistical power. As this trial
was intended primarily to characterize the safety of the
switch in therapies, the enrolled sample size of 73 was
deemed adequate for this purpose. For the present ana-
lysis, only data for those subjects who completed the
TSQM at baseline and week 12 were included. Of 73 sub-
jects enrolled in the original trial, 7 were not included in
this analysis due to missing TSQM data. The proportion
non-idiopathic PAH was higher in the excluded subjects
(71%) compared to those included in this analysis (50%),
but they were otherwise similar in terms age, sex, race,
WHO functional class, background PAH therapy, and 6-
minute walk distance. Internal consistency was assessed
using Cronbach’s alpha, a coefficient of reliability that in-
dicates how closely related a set of items are to one an-
other. Internal consistency was also assessed by examining
intrascale correlations among the individual domains of
the TSQM. Convergent validity of TSQM domains was
assessed in relation to absolute change in 6MWD from
baseline to week 12, percent change in total medication
administration time from baseline to week 12, and
severity-weighted AE score calculated for all AEs collected
up to week 12. Based on the non-normal distribution
exhibited by certain variables, a non-parametric approachwas applied for all correlations (i.e., Spearman’s coeffi-
cients). Responsiveness of the TSQM and its individual
domains was assessed in relation to the Patient Impression
of Change scale. Longitudinal change in TSQM scores
approximated a normal distribution, thus parametric test-
ing for differences among Patient Impression of Change
categories was performed using analysis of variance
(ANOVA). The relationship between change in TSQM
and change in CAMPHOR QoL scores was evaluated
using simple (unadjusted) and multiple (adjusted) linear
regression. Covariates in adjusted analyses included age,
sex, race, etiology of PAH (idiopathic vs. non-idiopathic),
WHO functional class, and type of background therapy
(endothelin receptor antagonist and phosphodiesterase in-
hibitor). Statistical analyses were performed using SASW
software, version 9.2 (SAS Institute Inc., Cary, NC).
Results
Baseline characteristics for 66 subjects included in this
analysis are shown in Table 1. Mean age was 49 years,
with a range 18–79 years. Subjects were predominantly
female (77%) and white (88%). Half (50%) of subjects
had idiopathic/heritable PAH. At baseline, 58% subjects
were WHO functional class II and 42% were functional
class III. Mean ± standard deviation (SD) 6MWD at
baseline was 395 ± 79 m.
All subscales of the TSQM showed high internal
consistency, both on inhaled iloprost (baseline) and on
inhaled treprostinil (week 12), with Cronbach alphas
ranging from 0.88 to 0.93 (Table 2). On inhaled iloprost
(baseline), the global satisfaction domain of the TSQM
correlated more strongly (r = 0.79) with effectiveness than
with either side effects or convenience (r = 0.23 and 0.42).
On inhaled treprostinil (week 12), a similar pattern of
correlations was observed, but with a much stronger
correlation between global satisfaction and convenience
(r = 0.73).
As shown in Table 3, transition from inhaled iloprost to
inhaled treprostinil was associated with a significant im-
provement in all TSQM domains (effectiveness: +20 ± 21
points, convenience: +39 ± 26 points, global satisfaction:
+20 ± 24 points), except for side effects, which remained
approximately the same (0 ± 22 points). Of the 4 TSQM
domains, convenience demonstrated the greatest increase.
Parallel improvements were observed for 6MWD and
medication administration time. From baseline to week
12, mean 6MWD improved by 16 ± 35 m and mean total
medication administration time decreased by 80 ± 81 -
minutes/day. Reduction in the time required for inhalation
(decrease of −53 ± 37 minutes/day) accounted for the
largest proportion of the reduction in total medication ad-
ministration time.
Convergent validity of the TSQM subscales was evalu-
ated with respect to related study measures assessed
Table 1 Baseline characteristics of 66 subjects with PAH
on inhaled prostacyclin
Characteristic Baseline (n = 66)
Age, mean (range), yr 49 (18 – 74)
Male : Female, n (%) 15 (23) : 51 (77)
White* 58 (88)
PAH etiology, n (%)
Idiopathic/heritable 33 (50)
Collagen vascular disease 13 (20)
Congenital heart disease 17 (26)
HIV 3 (5)
Background PAH therapy, n (%)
Endothelin receptor antagonist 56 (85)
Phosphodiesterase-5 inhibitor 46 (70)
Both 39 (59)
None 3 (5)
WHO functional class, n (%)
II 38 (58)
III 28 (42)
6-minute walk distance, mean ± SD, m 395 ± 79
Borg dypnea score, mean ± SD 3.4 ± 2.1
Iloprost dose, n (%)
2.5 μg 4 (6)
5.0 μg 62 (94)
Iloprost frequency
< 6 times per day 25 (38)
≥ 6 times per day 41 (62)
* n = 58 (8 missing).




Side effects 0.93 0.21 (p =
Convenience* 0.91 0.26 (p =
Global satisfaction 0.93 0.79 (p < 0
At 12 weeks (on
Effectiveness 0.90 1.00
Side effects 0.88 0.54 (p < 0
Convenience 0.91 0.51 (p < 0
Global satisfaction† 0.93 0.78 (p < 0
* 1 missing.
† 2 missing.
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baseline to week 12 correlated with change in 6MWD in
the expected manner, with the effectiveness domain dem-
onstrating the strongest correlation. Changes in TSQM
scores did not correlate significantly with percent change
in medication administration time. TSQM scores at week
12 correlated with severity-weighted AE score in the
expected manner (inversely), with the effectiveness and side
effects domains demonstrating the strongest correlations.
Responsiveness of the TSQM to change was evaluated
with respect to overall Patient Impression of Change
(Table 5). Of 61 patients who completed the Patient
Impression of Change item, 42 (69%) responded “much
more satisfied”, 18 (30%) responded “more satisfied”, and 1
(2%) responded “less satisfied”. Subjects who were “much
more satisfied” had greater improvement in global satisfac-
tion (+23 ± 24 points), as measured by the TSQM, than
subjects who were “more satisfied” (+14 ± 22 points) or
“less satisfied” (−21 ± 0 points). A similar pattern was ob-
served for the effectiveness and convenience domains, but
not for side effects. Standardized effect sizes observed
(Table 3) also supported the overall responsiveness of the
instrument.
The relationships between change in TSQM scores and
change in QoL, as measured by the CAMPHOR, are
shown in Table 6. Observed changes in effectiveness,
convenience, and global satisfaction were associated with
change in QoL, with greater satisfaction corresponding to
greater QoL. Change in side effects was not significantly
associated with QoL. A similar pattern of findings was
observed after adjusting for subject characteristics. Of the
4 domains, effectiveness explained the greatest proportion
of variance in QoL scores (adjusted Model R2 = 0.12).
Discussion
Patients with PAH are confronted with a growing number
of therapeutic options, each of which is associated with itse TSQM at baseline and at 12 weeks
ness Side effects Convenience
n iloprost)
0.10) 1.00
0.03) 0.13 (p = 0.29) 1.00
.0001) 0.23 (p = 0.06) 0.42 (0.0005)
treprostinil)
.0001) 1.00
.0001) 0.44 (p = 0.0002) 1.00
.0001) 0.52 (p < 0.0001) 0.73 (p < 0.0001)
Table 3 Changes in TSQM, 6MWD, medication administration time, and adverse events associated with transitioning
from inhaled iloprost to inhaled treprostinil
Baseline Week 12 Absolute change Standard effect size p
TSQM, mean ± SD
Effectiveness 62 ± 10 82 ± 16 +20 ± 21 2.0 <0.0001
Side effects 85 ± 21 85 ± 18 0 ± 22 0 0.97
Convenience 44 ± 24 83 ± 17 +39 ± 26 1.6 <0.0001
Global satisfaction 61 ± 23 82 ± 18 +20 ± 24 0.9 <0.0001
6-minute walk distance, mean ± SD, m 395 ± 79 414 ± 84 +16 ± 35 0.2 0.0005
Medication administration time, mean ± SD, min./day
Gather supplies 21 ± 24 12 ± 11 −9 ± 26 0.4 0.01
Prepare system 11 ± 8 9 ± 9 −2 ± 12 0.3 0.16
Inhalation 66 ± 35 13 ± 7 −53 ± 37 1.5 <0.0001
Clean 21 ± 47 5 ± 4 −16 ± 46 0.3 0.01
Total time 119 ± 78 39 ± 25 −80 ± 81 1.0 <0.0001
Adverse events, median (IQR)
Severity-weighted adverse event score – 4.4 ± 2.8 – – –
IQR: interquartile range.
6-minute walk distance missing for 2 subjects.
Medication administration time missing data for 5 subjects.
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tive effectiveness data exists, patient preferences can often
be the driving factor behind choice of therapy. Thus, treat-
ment satisfaction is likely to be highly relevant in the
management of PAH. In this study, we evaluated the psy-
chometric characteristics of a relatively new treatment sat-
isfaction measure, the TSQM, assessed among patients
participating in a 12 week open-label study of inhaled
PAH therapy. We found that transitioning from inhaled
iloprost to inhaled treprostinil was associated with signifi-
cant improvements in treatment satisfaction as measured
by the TSQM. Domains of treatment satisfaction impacted
included global satisfaction, effectiveness, and convenience,
but not side effects. Overall, the TSQM showed high in-
ternal consistency, good convergent validity, and evidence
of responsiveness to change over 12 weeks. Increases in
treatment satisfaction were significantly associated with im-
provement in QoL independent of subject characteristics.Table 4 Correlation between TSQM and 6MWD, medication a




Effectiveness 0.43 (p = 0.0004)
Side effects 0.18 (p = 0.15)
Convenience 0.24 (p = 0.06)
Global
satisfaction
0.29 (p = 0.02)
* Compared to change in TSQM from Baseline to Week 12.
† Compared to TSQM at Week 12.
Medication administration time missing data for 5 subjects.Little is known about the determinants of treatment sat-
isfaction in PAH. In a previous pilot study, we evaluated
changes in treatment satisfaction using the TSQM among
10 patients with PAH transitioning from continuous intra-
venous epoprostenol to intravenous treprostinil [28]. In
that study, a significant impact was observed in all do-
mains of the TSQM at 8 weeks. Changes in treatment
satisfaction were accompanied by improvement in QoL
scores and a decrease in total time spent on drug prepa-
ration activities. Based on these favorable results, we uti-
lized a similar approach in designing the current study of
inhaled prostacyclin among a substantially larger popula-
tion of patients with PAH [17,18]. Our findings support
the reliability, validity, and responsiveness of the TSQM in
PAH, while providing additional insights regarding its
relationship with other health status measures.
In the case of inhaled prostacyclins, we found that





0.04 (p = 0.79) −0.45 (p = 0.0002)
0.18 (p = 0.17) −0.44 (p = 0.0002)
0.14 (p = 0.28) −0.36 (p = 0.003)
0.14 (p = 0.30) −0.35 (p = 0.005)
Table 5 Responsiveness of TSQM to patient-assessed global impression of change
Patient impression of change (Baseline to week 12)*
Same or less satisfied* (n = 1) More satisfied (n = 18) Much more satisfied (n = 42) p†
Change in TSQM, mean ± SD
Effectiveness −28 ± 0 +13 ± 18 +23 ± 21 0.02
Side effects −75 ± 0 −2 ± 20 +3 ± 20 0.001
Convenience +6 ± 0 +22 ± 18 +45 ± 26 0.002
Global satisfaction −21 ± 0 +14 ± 22 +23 ± 24 0.10
Positive change in score indicates improvement.
5 missing.
* Includes any responses for “about the same”, “less satisfied”, or “much less satisfied”.
† ANOVA.
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tion as perceived by the patient. Significant correla-
tions between change in treatment satisfaction and
change in 6MWD further corroborate this finding.
Nonetheless, convenience also appears to play a major
role. Among the 4 treatment satisfaction domains,
convenience appeared the most responsive to transi-
tion from inhaled iloprost to inhaled treprostinil.
Parallel improvements in medication administration
time were also observed, however, these changes did
not correlate significantly with change in treatment
satisfaction. One potential explanation for the lack of
association is that additional factors (other than time
spent administering medication) may have a signifi-
cant impact on convenience. For example, particular
features associated with the delivery device, such as
ease of operation, need for cleaning/maintenance, and
portability may be equally, or even more, important.
Another explanation is that our study may not be
adequately powered to detect weaker associations,
although trends in the anticipated direction of effect
were observed. In addition to convenience, sideTable 6 Relationship between change in TSQM and
change in CAMPHOR QoL score
Predictor Model R2 Standardized β ± SE p
Unadjusted Model
Effectiveness 0.13 −0.07 ± 0.02 0.002
Side effects <0.01 −0.01 ± 0.02 0.81
Convenience 0.09 −0.05 ± 0.02 0.008
Global satisfaction 0.06 −0.05 ± 0.02 0.03
Adjusted Model
Effectiveness 0.12 −0.07 ± 0.02 0.002
Side effects <0.01 −0.02 ± 0.03 0.50
Convenience 0.08 −0.05 ± 0.02 0.01
Global satisfaction 0.03 −0.04 ± 0.02 0.05
Adjusted model includes age, sex, race, etiology of PAH, WHO functional class,
and type of background therapy.effects can also have a significant impact on treat-
ment satisfaction as indicated by significant correla-
tions with adverse events at week 12. In this study,
however, we could not evaluate impact of changes in
adverse events since they were not collected at base-
line for iloprost. In spite of this, the lack of any
change in the side effects domain of the TSQM
suggests that treprostinil and iloprost may have similar
side effect profiles.
Several limitations should be considered in the
interpretation of our data. Most importantly, although
the study was conducted in a prospective fashion, the
relationships evaluated in our analysis utilized mea-
sures assessed concurrently. Consequently, causality
cannot be inferred. Based on our findings, it is pos-
sible that improvement in 6MWD and reduction in
medication administration time could have lead to the
observed increase treatment satisfaction, but this
remains speculative. Moreover, it is difficult to deter-
mine whether increased treatment satisfaction resulted
in improved QoL, or vice versa. Cross-lagged panel
models have been developed to address such temporal
associations, but are require substantially more data.
As previously mentioned, our small sample size also
limits our ability to detect what may be modest,
albeit meaningful relationships. Ideally, a varied range
of responses is required in order to fully evaluate the
responsiveness of an instrument. In the case of our
results, our ability to demonstrate the responsiveness
of the TSQM may have been limited by the fact that
nearly all patients reported improvements in treat-
ment satisfaction. Similar side effect profiles between
the two inhaled prostacyclins may have also precluded
our ability to assess responsiveness in this regard.
Finally, our results are also vulnerable to potential
selection bias insofar as patients who are currently
dissatisfied with their current treatment (iloprost) may
be more likely to have enrolled into the trial. Exclu-
sion of patients with missing data for treatment satis-
faction could have also introduced bias if the patients
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less likely to be satisfied) than those included.
In summary, changes in treatment satisfaction in pa-
tients transitioning from inhaled iloprost to inhaled
treprostinil were associated with increased exercise cap-
acity and improved QoL. The TSQM demonstrates rea-
sonable performance characteristics in patients with PAH
and may be a useful tool for comparing satisfaction with
PAH therapies, in particular, those requiring different
delivery routes or dosing regimens.
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